 |
|
New Cause of Tamoxifen Resistance in Breast Cancer Cells Discovered at Lombardi
August 13, 2007Washington, DC--When a woman receives a breast cancer diagnosis her entire life may change in the blink of an eye. But the nature of that change is governed by the smallest alterations that take place within the proteins of the tumor cells, determining what treatments she can pursue with a hope of cure and those to which her cancer is resistant.
Scientists from the Lombardi Comprehensive Cancer Center announced today the discovery of a new mechanism of resistance to endocrine or anti-hormonal therapies, such as Tamoxifen and Faslodex. This research may allow oncologists to screen women for responsiveness to these treatments, and provides a much-needed clue to reversing resistance. The research, led by Robert Clarke, PhD, DSc, a professor of oncology and of physiology and biophysics at Georgetown University Medical Center, indicates that a gene previously thought to be unrelated to breast cancer may be responsible for some resistance to endocrine therapy.
The gene, called human X-box binding protein-1 (XBP1), is an alternatively spliced transcription factor that participates in a stress-signaling pathway to protect cells from damage. In a paper published online in the Journal of the Federation of American Societies for Experimental Biology (FASEBJ) on July 27, Clarke and his colleagues at the Lombardi Comprehensive Cancer Center (part of Georgetown University Medical Center) found that over-expression of the spliced variant of the gene in estrogen receptor-positive breast cancer cells led to reduced sensitivity to Tamoxifen and Faslodex.
According to Lombardi medical oncologist Minetta Liu, MD, it is expected that all hormone receptor positive metastatic breast cancers will eventually develop resistance to endocrine therapies. When this happens, doctors must switch their patients to a different class of drugs - throwing their lives into limbo once again as treatment schedules are changed and new side effects develop.
"When cell lines changed from being sensitive to endocrine therapy to being resistant, we saw an increase in spliced XBP1 inside the cell. So then we took sensitive cells and added spliced XBP1, which made them resistant to the therapy," explained Clarke, who is interim director of Georgetown's Biomedical Graduate Research Organization and co-leader of the Breast Cancer Program at the Lombardi Comprehensive Cancer Center.
Anti-hormonal therapies are some of the most effective treatments for breast cancer because estrogen, a natural female sex hormone, can drive the growth of the tumor. Tamoxifen and other anti-hormonal therapies cut off the tumor's access to estrogen, causing the tumor to stabilize and sometimes even shrink. However according to Clarke, many cancers become insensitive to these treatments over time - more than half of all recurring breast cancers lose sensitivity - because they have found a way to keep growing in the absence of estrogen.
Previously, Clarke and his team found that XBP1 is co-expressed with the estrogen receptor in breast tumor cells. This may mean that the effects of XBP1 over-expression occur when the protein is bound to the estrogen receptor, suggesting for the first time that these two proteins interact in the cell. This was the first evidence that the XBP1 protein may play a role in breast cancer pathways.
Through molecular profiling of the downstream effects of the spliced XBP1, Dr. Clarke and his colleagues discovered that expression of several anti-apoptotic genes responsible for programmed cell death - including BCL2 - are altered. While they have not yet determined the exact interactions that take place, the researchers believe that the overexpression of XBP1 promotes cell survival by affecting the activity of the intrinsic apoptosis pathway.
"XBP1 may give us a much-needed clue for better predicting response to anti-estrogen therapies like Tamoxifen," explained Clarke. "The presence of the activated protein at high levels should predict estrogen independence and thus resistance to these therapies."
In the future, Clarke also hopes to develop a new therapeutic treatment based on this discovery. He believes that the XBP1 pathway can be targeted in patients receiving treatment to ensure their tumors do not become resistant to the anti-hormonal therapies. Using this discovery, Clarke also hopes to find a way to reverse resistance to anti-hormonal therapies, making it possible for women to continue treatment with first line therapies for longer.
However, Clarke said that the next step in this research will be to conduct a trial to test the predictive power of XBP1 in the clinic.
About Lombardi Comprehensive Cancer Center
The Lombardi Comprehensive Cancer Center, part of Georgetown University Medical Center and Georgetown University Hospital, seeks to improve the diagnosis, treatment, and prevention of cancer through innovative basic and clinical research, patient care, community education and outreach, and the training of cancer specialists of the future. Lombardi is one of only 39 comprehensive cancer centers in the nation, as designated by the National Cancer Institute, and the only one in the Washington, DC, area. For more information, go to http://lombardi.georgetown.edu.
About Georgetown University Medical Center
Georgetown University Medical Center is an internationally recognized academic medical center with a three-part mission of research, teaching and patient care (through our partnership with MedStar Health). Our mission is carried out with a strong emphasis on public service and a dedication to the Catholic, Jesuit principle of cura personalis -- or "care of the whole person." The Medical Center includes the School of Medicine and the School of Nursing and Health Studies, both nationally ranked, the world-renowned Lombardi Comprehensive Cancer Center and the Biomedical Graduate Research Organization (BGRO), home to 60 percent of the university's sponsored research funding.
Georgetown University Medical Center
According to Lombardi medical oncologist Minetta Liu, MD, it is expected that all hormone receptor positive metastatic breast cancers will eventually develop resistance to endocrine therapies. When this happens, doctors must switch their patients to a different class of drugs - throwing their lives into limbo once again as treatment schedules are changed and new side effects develop.
"When cell lines changed from being sensitive to endocrine therapy to being resistant, we saw an increase in spliced XBP1 inside the cell. So then we took sensitive cells and added spliced XBP1, which made them resistant to the therapy," explained Clarke, who is interim director of Georgetown's Biomedical Graduate Research Organization and co-leader of the Breast Cancer Program at the Lombardi Comprehensive Cancer Center.
Anti-hormonal therapies are some of the most effective treatments for breast cancer because estrogen, a natural female sex hormone, can drive the growth of the tumor. Tamoxifen and other anti-hormonal therapies cut off the tumor's access to estrogen, causing the tumor to stabilize and sometimes even shrink. However according to Clarke, many cancers become insensitive to these treatments over time - more than half of all recurring breast cancers lose sensitivity - because they have found a way to keep growing in the absence of estrogen.
Previously, Clarke and his team found that XBP1 is co-expressed with the estrogen receptor in breast tumor cells. This may mean that the effects of XBP1 over-expression occur when the protein is bound to the estrogen receptor, suggesting for the first time that these two proteins interact in the cell. This was the first evidence that the XBP1 protein may play a role in breast cancer pathways.
Through molecular profiling of the downstream effects of the spliced XBP1, Dr. Clarke and his colleagues discovered that expression of several anti-apoptotic genes responsible for programmed cell death - including BCL2 - are altered. While they have not yet determined the exact interactions that take place, the researchers believe that the overexpression of XBP1 promotes cell survival by affecting the activity of the intrinsic apoptosis pathway.
"XBP1 may give us a much-needed clue for better predicting response to anti-estrogen therapies like Tamoxifen," explained Clarke. "The presence of the activated protein at high levels should predict estrogen independence and thus resistance to these therapies."
In the future, Clarke also hopes to develop a new therapeutic treatment based on this discovery. He believes that the XBP1 pathway can be targeted in patients receiving treatment to ensure their tumors do not become resistant to the anti-hormonal therapies. Using this discovery, Clarke also hopes to find a way to reverse resistance to anti-hormonal therapies, making it possible for women to continue treatment with first line therapies for longer.
However, Clarke said that the next step in this research will be to conduct a trial to test the predictive power of XBP1 in the clinic.
About Lombardi Comprehensive Cancer Center
The Lombardi Comprehensive Cancer Center, part of Georgetown University Medical Center and Georgetown University Hospital, seeks to improve the diagnosis, treatment, and prevention of cancer through innovative basic and clinical research, patient care, community education and outreach, and the training of cancer specialists of the future. Lombardi is one of only 39 comprehensive cancer centers in the nation, as designated by the National Cancer Institute, and the only one in the Washington, DC, area. For more information, go to http://lombardi.georgetown.edu.
About Georgetown University Medical Center
Georgetown University Medical Center is an internationally recognized academic medical center with a three-part mission of research, teaching and patient care (through our partnership with MedStar Health). Our mission is carried out with a strong emphasis on public service and a dedication to the Catholic, Jesuit principle of cura personalis -- or "care of the whole person." The Medical Center includes the School of Medicine and the School of Nursing and Health Studies, both nationally ranked, the world-renowned Lombardi Comprehensive Cancer Center and the Biomedical Graduate Research Organization (BGRO), home to 60 percent of the university's sponsored research funding.
Georgetown University Medical Center
Breast Cancer Current Events and Breast Cancer News RSSStudy identifies causes of bone loss in breast cancer survivors
Osteoporosis is a growing concern among breast cancer survivors and their doctors, because certain cancer drugs can cause bone loss.
2 new compounds show promise for eliminating breast cancer tumors
Two new compounds created by a University of Central Florida professor show early promise for destroying breast cancer tumors.
UNC researchers find clue to stopping breast-cancer metastasis
If scientists knew exactly what a breast cancer cell needs to spread, then they could stop the most deadly part of the disease: metastasis. New research from the University of North Carolina at Chapel Hill School of Medicine takes a step in that direction.
Fear, misconceptions about screenings keep many African-Americans from getting mammograms
Training physicians and caregivers to improve cultural sensitivity and communication with economically disadvantaged African-American patients could influence these women to get mammograms that could save their lives.
New technology could revolutionize breast cancer screening
The world's first radar breast imaging system developed at Bristol University that could revolutionise the way women are scanned for breast cancer, is being trialled at North Bristol NHS Trust (NBT).
Battling bacteria in the blood: Researchers tackle deadly infections
It's a leading cause of death, but no one knows for sure how and why it happens. It's a major source of health care costs, adding days or weeks to the hospital stays and lost work time of millions of people. But no one fully understands how best to fight it.
Mayo Clinic Study Finds Risk Assessment Tool Not Reliable Predictor for Some Women at High Risk of Breast Cancer
A statistical model commonly used to predict the risk of breast cancer in women was not accurate when used to evaluate women with atypical hyperplasia, according to a new Mayo Clinic study published in the Oct. 14, 2008, issue of the Journal of Clinical Oncology.
Migraines associated with lower risk of breast cancer
Women who suffer from migraines may take at least some comfort in a recent, first-of-its-kind study that suggests a history of such headaches is associated with a significantly lower risk of breast cancer.
Folic acid, B vitamins do not appear to affect cancer risk
A daily supplementation combination that included folic acid and vitamin B6 and B12 had no significant effect on the overall risk of cancer, including breast cancer, among women at high risk of cardiovascular disease, according to a study in the November 5 issue of JAMA.
Healthy bones program reduces hip fractures by 37 percent
Proactive measures can reduce hip fracture rates by an average of 37.2 percent -- and as much as 50 percent -- among those at risk, according to a study conducted by Kaiser Permanente Southern California. The study was published online on November 3 by The Journal of Bone & Joint Surgery, a peer-reviewed journal.
More Breast Cancer Current Events and Breast Cancer News Articles
 | Breast Cancer Husband : How to Help Your Wife (and Yourself) during Diagnosis, Treatment and Beyond by Marc Silver A unique guide, like none other on the market-packed with medical information, practical tips, psychological insight, and coping strategies-to help men help the women they love through this trying time. When Marc Silver became a breast cancer husband three years ago, he learned firsthand how frightened and helpless the breast cancer husband feels. He searched in vain for a book that would give... |
 | Chicken Soup for the Breast Cancer Survivor's Soul: Stories to Inspire, Support and Heal (Chicken Soup for the Soul) by Jack Canfield, Mark Victor Hansen, Mary Olsen Kelly Your support group in a book, filled with boundless strength and profound hope - until the fight is won. Along with the shock, fear and loss many women face upon a breast cancer diagnosis comes unexpected strength, wisdom, and strong networks of sharing, support and healing. In Chicken Soup for the Breast Cancer Survivor's Soul, survivors and their family members talk openly about how difficult... |
 | Choices in Breast Cancer Treatment: Medical Specialists and Cancer Survivors Tell You What You Need to Know (A Johns Hopkins Press Health Book) A diagnosis of breast cancer can be overwhelming. The disease is frightening and the medical landscape confusing. In the wake of fear and confusion comes the need to make decisions about treatment. This book provides women with medically reliable and up-to-date information to help them with these decisions.Within these pages is a team of private consultants -- including surgeons, medical... |
 | The Breast Cancer Survivor's Fitness Plan (Harvard Medical School Guides) by Carolyn M. Kaelin, Francesca Coltrera, Josie Gardiner, Joy Prouty The only breast cancer recovery program designed by a Harvard doctor and survivor and approved by the American Council on Exercise (ACE) Feel healthy again. Regain control of your life. Exciting new research reveals that regular exercise can reduce the chance of breast cancer recurrence and extend your life. Exercise can also help you recover energy, strength, and flexibility diminished by... |
 | Breast Cancer Survival Manual, Fourth Edition: A Step-by-Step Guide for the Woman With Newly Diagnosed Breast Cancer by John Link A completely updated edition of the definitive guide for patients with breast cancer The new fourth edition of The Breast Cancer Survival Manual provides essential updates on treatment and care, enhancing the basic information that has made this the most trusted guide for women diagnosed with breast cancer for the past decade. This edition includes the most current advice on • getting a second... |
 | What Your Doctor May Not Tell You About(TM): Breast Cancer: How Hormone Balance Can Help Save Your Life (What Your Doctor May Not Tell You About...) by John R. Lee, David Zava, Virginia Hopkins An informative and absorbing read for both medical practitioners and their patients, What Your Doctor May Not Tell You About Breast Cancer takes aim at "the breast cancer industry" with a barrage of thought-provoking ammunition. The book is equal parts criticism and suggestion. Current health treatments, including HRT, receive serious condemnation, and authors John Lee and David Zava carefully... |
 | Breast Cancer: Real Questions, Real Answers by David Chan Breast Cancer: Real Questions, Real Answers is an outgrowth of Dr. David Chan's more than 20 years in private oncology practice. Inspired by his patients—who courageously face their illness but often feel fearful, confused about their options, and full of questions—Dr. Chan's book is uniquely structured as a Question and Answer between patient and doctor. It provides readers with an easily... |
 | I Am Not My Breast Cancer: Women Talk Openly About Love and Sex, Hair Loss and Weight Gain, Mothers and Daughters, and Being a Woman with Breast Cancer by Ruth Peltason I Am Not My Breast Cancer gathers the warm, loving, frank, and informed voices of more than eight hundred women—from every state in the nation and from continents as far away as Australia and Africa—who reveal their fears, trade advice, share experiences, and express their deepest, most intimate concerns. Essential reading for any woman with this diagnosis, it offers the companionship of... |
 | The Breast Cancer Prevention Diet: The Powerful Foods, Supplements, and Drugs That Can Save Your Life by Dr. Bob Arnot "From one of the most visible and highly respected figures in medical journalism comes a book that can literally save lives. During the past several years, doctors at leading institutions across the nation have been investigating the relationship between breast cancer and diet. The recent flood of medical studies confirm that what a woman eats can have a dramatic impact on whether or not... |
 | Living Through Breast Cancer - PB by Carolyn M. Kaelin Winner of two prestigious American Medical Writers Association awards A compassionate guide to surviving breast cancer from a doctor who has experienced it from both sides of the stethoscope In addition to being a leading national breast cancer expert and a highly respected cancer surgeon, Dr. Carolyn Kaelin also is a breast cancer survivor. In Living Through Breast Cancer she draws upon her... |
| © 2008 BrightSurf.com |